Fujian Haixi Pharmaceuticals Co Ltd (HKSE:02637) Share Price

Company Profile

Business description
Fujian Haixi Pharmaceuticals Co Ltd is a commercial-stage pharmaceutical company that integrates R&D, production and sales capacities, with a pipeline of inventive drug candidates. It has a diversified product portfolio and pipeline in the fastest growing therapeutic areas in China. The company's commercialized product portfolio consisted of generic drugs for digestive system diseases, cardiovascular system diseases, endocrine system diseases, nervous system diseases and inflammatory diseases. Its inventive drug pipeline focuses on drug candidates in a variety of indications, including one potential first-in-class oncology drug candidate, one potential first oral drug therapy for wet age-related macular degeneration /diabetic macular edema /retinal vein occlusion.
Contact
No. 177 Jinda Road
Floor 3rd & 4th, Block B
Jianxin Town
Cangshan District,Fujian Province
Fuzhou350028
CHN
T: +86 59187519936
https://www.hxpharma.com
Sector
Healthcare
Stock type
Defensive
Industry
Drug Manufacturers - Specialty & Generic
Fiscal Year End
31 December 2026
Employees
203

Recommended

Microsoft’s earnings report is expected to touch on AI adoption and monetization.

Dan Romanoff, CPA | 23 April 2026

The ongoing war is likely to keep commodity prices even more volatile than usual until it is resolved.

Jon Mills, CFA | 23 April 2026

How investors can uncover value beyond the index heavyweights.

Tyger Fitzpatrick | 23 April 2026

Index	Last price	Change	% Change
All Ordinaries	9,024.20	27.20	-0.30%
CAC 40	8,227.32	70.89	0.87%
DAX 40	24,155.45	39.45	-0.16%
Dow JONES (US)	49,310.32	179.71	-0.36%
FTSE 100	10,457.01	19.45	-0.19%
HKSE	25,915.20	248.04	-0.95%
NASDAQ	24,438.50	219.06	-0.89%
Nikkei 225	59,140.23	445.63	-0.75%
NZX 50 Index	12,884.93	60.67	-0.47%
S&P 500	7,108.40	29.50	-0.41%
S&P/ASX 200	8,793.40	26.10	-0.30%
SSE Composite Index	4,093.25	13.01	-0.32%